洛特生化公司任命詹姆斯·朴为新的首席执行官,以加强全球扩张努力。 Lotte Biologics appoints James Park as new CEO to enhance global expansion efforts.

Lotte Biologics是Lotte集团的子公司,已任命James Park为新的首席执行官,以提升其全球市场存在。 Lotte Biologics, a subsidiary of Lotte Group, has appointed James Park as its new CEO to boost its global market presence. Park以前是GC Cell的首席执行官,在Merck和Samsung Biologics等公司工作过,预计会帮助该公司在国际上扩展。 Park, previously CEO of GC Cell and with experience at companies like Merck and Samsung Biologics, is expected to help the company expand internationally. 该任命正在等待股东会议。 The appointment is pending a shareholders' meeting.